7801 North Capital of Texas Highway
Austin, TX 78731
512 501 2444
Empleados a tiempo completo: 24
|Nombre||Título||Paga||Ejecutado||Año de nacimiento|
|Mr. Remi Barbier||Founder, Chairman, Pres & CEO||1,74M||114,86k||1960|
|Mr. Eric J. Schoen||Chief Financial Officer||776,93k||N/A||1968|
|Dr. James W. Kupiec M.D.||Chief Medical Officer||476,57k||N/A||N/A|
|Dr. George Thornton||Sr. VP of Technology||N/A||N/A||N/A|
|Mr. R. Christopher Cook||Sr. VP & Gen. Counsel||N/A||N/A||N/A|
|Mr. Michael Zamloot||Sr. VP of Technical Operations||N/A||N/A||N/A|
|Dr. Michael Marsman Pharm.D.||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
|Dr. Lindsay H. Burns Ph.D.||Sr. VP of Neuroscience||N/A||N/A||N/A|
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
El ISS Governance QualityScore de Cassava Sciences, Inc., a día 1 de febrero de 2023, es 10. Las puntuaciones base son Auditoría: 10; Tablero: 10; Derechos de los accionistas: 8; Compensación: 8.